108 results on '"Osman, Keren"'
Search Results
2. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter
3. Myocardial Amyloid Quantification with Look-Locker Magnetic Resonance Sequence in Cardiac Amyloidosis. Diagnostic Accuracy in Clinical Practice and Histological Validation
4. CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease.
5. Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory solid organ transplant‐related PTLD.
6. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation
7. A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe ARDS From COVID-19.
8. Phase 1/2 study of ixazomib with cyclophosphamide and dexamethasone in newly diagnosed AL amyloidosis
9. Safety and Efficacy of Triplet Regimens in Newly Diagnosed Light Chain Amyloidosis
10. Characterization of Infectious Complications during the Expected Duration of Cytokine Release Syndrome (CRS) in Patients Receiving CAR T Cell Therapy – Are We over-Treating with Anti-Microbials?
11. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization
12. Cardiac magnetic resonance evaluation of left ventricular remodelling distribution in cardiac amyloidosis
13. Retrospective analysis of prognosticators in patients with relapsed Hodgkin’s Lymphoma treated with autologous transplant: results of a single center
14. Combination strategies to enhance antitumor ADCC
15. Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma
16. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma
17. A case report of secondary autograft failure due to Gaucher disease
18. 253 - Safety, Efficacy, and Outcomes of CD19 CAR T Cell Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD) in the Real World Setting
19. 234 - Patient-Reported Outcomes (PROs) in Zuma-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
20. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
21. Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma
22. CD19-Targeted CAR T Cell Therapy for Concomitant Diffuse Large B Cell Lymphoma and Myeloma
23. Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD)
24. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig VL germ line gene use and clonal plasma cell burden
25. 115 - Clinical Program Manager and Nurse Practitioner Specializing in Immune Effector Cell Therapy
26. Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.
27. The Hematologist's Role in Amyloidosis Management: Disease Awareness, Diagnostic Workup, and Practice Patterns
28. Cytopenias Following CAR-T Cell Therapy - a Single Center Experience
29. A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis
30. 26 - Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
31. Long Term Follow up of Patients with Relapsed/Refractory Systemic Light Chain (AL) Amyloidosis Treated with Bendamustine and Dexamethasone in a Phase 2 Study
32. 156 - Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
33. 162 - Timing of Influenza Vaccine Response in Patients That Receive Autologous Hematopoietic Cell Transplantation
34. Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis
35. Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
36. Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib
37. Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
38. Bendamustine-Brentuximab: Bridging to Transplant
39. Secondary Graft Failure in Allogeneic Stem Cell Transplantation for Myelofibrosis - a Single Institution Experience
40. Donor Cell Cardiac Myeloid Sarcoma Following Umbilical Cord Transplantation
41. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment.
42. Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis
43. Palifermin Use in Lymphoma Patients Undergoing Autologous BEAM Transplants
44. Oral Glutamine and Probiotics on Enteral Morbidity Following Autologous Stem Cell Transplantation for Plasma Cell Dyscrasias
45. Graft Versus Host Disease After Stem Cell Allotransplantation With Low-Dose Total Body Irradiation, Fludarabine, and Antithymocyte Globulin.
46. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients.
47. Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,
48. Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis.
49. Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019.
50. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.